PKM and non-small cell lung carcinoma: Inhibitors targeting PKM2 are believed to exert in vivo antitumor effects on xenografts derived from NSCLC by modulating biosynthesis and reducing the metabolic flux from glucose to lactate.172 However, it has been observed that PKM2 is not indispensable for tumorigenesis in specific models, prompting further investigation into the potential role of PKM2 inhibitors or activators, such as TEPP-46, in cancer therapy.